Literature DB >> 20152888

The proconvulsant effects of leptin on glutamate receptor-mediated seizures in mice.

James J Lynch1, Eugene W Shek, Vincent Castagné, Scott W Mittelstadt.   

Abstract

The metabolic-related hormone, leptin has been suggested for clinical use as an anticonvulsant based upon data generated from in vitro and in vivo non-human studies. However, a number of other non-human experiments have demonstrated proconvulsant activity for leptin. The current study investigated potential pro- and anticonvulsant effects of leptin during exposure to either glutamate (the major endogenous excitatory neurotransmitter) or three subtype-selective glutamate receptor agonists (N-methyl-d-aspartic acid [NMDA], alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA], and kainate). Male C57BL/6JRj mice were pretreated with leptin (0.1-10mg/kg, i.p.) and then administered doses of the glutamate receptor agonists (i.p.) that had been previously shown to result in clonic convulsions in approximately half of the animals tested. Leptin had no clear convulsant-related effects with either glutamate or AMPA, but it exhibited dose-related, proconvulsant activity (decreased latency to first occurrence of various convulsion-related signs, and increased percentage of animals exhibiting such signs) with both NMDA and kainate. The proconvulsant effects of leptin observed during the current study suggest that a cautious approach should be taken when administering leptin to individuals who may be prone to seizures. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20152888     DOI: 10.1016/j.brainresbull.2010.02.003

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  9 in total

Review 1.  The neuropathology of obesity: insights from human disease.

Authors:  Edward B Lee; Mark P Mattson
Journal:  Acta Neuropathol       Date:  2013-10-06       Impact factor: 17.088

2.  Anti-N-methyl-D-aspartate receptor encephalitis: a prospective study focused on cerebrospinal fluid and clinical symptoms.

Authors:  Shouyi Wu; Huiqin Li; Yajun Lian; Yuan Chen; Yake Zheng; Chengze Wang; Qiaoman Zhang; Zhi Huang; Zhengrong Mao; Kai Pang
Journal:  Neurol Sci       Date:  2020-05-12       Impact factor: 3.307

3.  Protective role of astrocytic leptin signaling against excitotoxicity.

Authors:  Bhavaani Jayaram; Reas S Khan; Abba J Kastin; Hung Hsuchou; Xiaojun Wu; Weihong Pan
Journal:  J Mol Neurosci       Date:  2012-11-23       Impact factor: 3.444

Review 4.  Leptin action on nonneuronal cells in the CNS: potential clinical applications.

Authors:  Weihong Pan; Hung Hsuchou; Bhavaani Jayaram; Reas S Khan; Eagle Yi-Kung Huang; Xiaojun Wu; Chu Chen; Abba J Kastin
Journal:  Ann N Y Acad Sci       Date:  2012-04-24       Impact factor: 5.691

Review 5.  Astroglial role in the pathophysiology of status epilepticus: an overview.

Authors:  Karina Vargas-Sánchez; Maria Mogilevskaya; John Rodríguez-Pérez; María G Rubiano; José J Javela; Rodrigo E González-Reyes
Journal:  Oncotarget       Date:  2018-06-01

6.  Leptin: role over central nervous system in epilepsy.

Authors:  Laura Mora-Muñoz; Alejandro Guerrero-Naranjo; Elisa Angélica Rodríguez-Jimenez; Claudio Alberto Mastronardi; Alberto Velez-van-Meerbeke
Journal:  BMC Neurosci       Date:  2018-09-05       Impact factor: 3.288

7.  Selenium and leptin levels in febrile seizure: a case-control study in children.

Authors:  Abolfazl Khoshdel; Neda Parvin; Maedeh Abbasi
Journal:  Korean J Pediatr       Date:  2013-02-25

Review 8.  Neuroactive peptides as putative mediators of antiepileptic ketogenic diets.

Authors:  Carmela Giordano; Maddalena Marchiò; Elena Timofeeva; Giuseppe Biagini
Journal:  Front Neurol       Date:  2014-04-29       Impact factor: 4.003

9.  Acute Phase Serum Leptin, Adiponectin, Interleukin-6, and Visfatin Are Altered in Chinese Children With Febrile Seizures: A Cross-Sectional Study.

Authors:  Jie-Ru Chen; Mei-Fang Jin; Ling Tang; Yue-Ying Liu; Hong Ni
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-15       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.